本帖最后由 老马 于 2013-3-13 13:43 编辑 |) m5 V$ i# K M5 D& t7 E/ @( V
* R0 d( Z# p; t: h
健择（吉西他滨）+顺铂+阿瓦斯汀3 B3 R' p% s4 F; C2 k! f
Gemzar +Cisplatin + Avastin
' s- p% k5 P+ S/ T0 [% ]; Y1 [http://annonc.oxfordjournals.org/content/21/9/1804.full( z0 ~ V6 }" B$ h0 V* {
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) & b# C# k* a X4 Q% U
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 4 D( \/ l9 y' N( ~. f4 E
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. A2 T; u2 ?2 @+ Z+ o
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1028)
: U$ R1 o* b% ?% p
华为网盘附件：' ^9 E- W8 p, w4 |& l
【华为网盘】ava.JPG
V, G7 L+ |6 {$ z0 k |
显身卡
